CD1
CD1a
CD2
CD3 § T cell marker § Cytoplasm of immature T cells and surface of more mature cells § Negative in NK cells § First line in acute T cell malignancies § Second line in chronic T cell disorders (proportion are negative for CD3)
CD4 § T-helper cells, monocytes, dendritic cells, activated eosinophils and thymocytes § Second line in chronic T cell lymphoproliferative disorders (+ in ATLL, Sezary, and some T-PLL)
CD5 § B and T cell marker § B cell malignancies - CLL, Mantle cell lymphoma § T cell - T-ALL
CD7 § Pro and Pre T cells, T cells, thymocytes and NK cells § Also positive on some myeloblasts § Second line T cell marker in acute leukaemias
CD8 § Cytotoxic T cells, NK cells, thymocytes § Second line in chronic T cell lymphoproliferative disorders § + in T-LGL leukaemia and some T-PLL (< than CD4), +/- in ALCL CD9
CD10 § B lymphoid (acute leukaemia) § Positive in common ALL – negative in Prepre / precursor B-ALL § Germinal centre cells and neutrophils § + Follicular lymphoma (60%), Large cell lymphoma (25-50%) and Burkitt § + AIL T NHL
CD11b
CD11c
CD13
CD14 § Monocytoid marker (also positive on macrophages, subsets of granulocytes and B cells but less strongly)
CD15 § Myeloid cells and monocytes § + in Hodgkin (Reed-Sternberg cells + in classical Hodkins) / - in B NHL lymphoma
CD16 § NK cell / LGL leukaemia
CD19 § B cell marker (first line in chronic lymphoproliferative disorders) – not positive in myeloma
CD20 § Mature B cell marker § Negative in myeloma and weak in CLL
CD21 § Mature B cell marker, follicular dendritic cells also a subset of thymocytes
CD22 § B cell marker (first line in chronic lymphoproliferative disorders)
CD23 § B cell marker (first line in chronic lymphoproliferative disorders)
CD 25 § Activated T cells § HTLV-1 associated ATLL § Hairy cell leukaemia
CD30 § + Reed – Sternberg cells – classical Hodkin’s § + Anaplastic large cell lymphoma
CD33 § Second line marker for AML § + in all subtypes of AML except M6 (M7 is +/-)
CD34 § Uncommitted haemopoietic progenitors (CD34+ / CD38-) § + in AML M0 / M1 § +/- in AML M2,4, 7 and – in AML M3, M5, M6
CD38 § Expression is a marker of initial lineage commitment § Plasma cell marker
CD40 § B cell
CD41 § Megakaryocitic marker – glycoprotein IIb § Second line marker for AML (+ in AML M7)
CD42 § Promegakaryocytic / megakaryocytic / platelet – glycoprotein Ib § Second line marker for AML
CD45 § Second line marker for non-lineage restricted haemopoietic cells § Negative in Hodgkins
CD45 RO § T cell marker
CD52 § Target for campath / alemtuzumab
CD56
CD57 § NK cells (particularly CD3+, CD8+)
CD61 § Megakaryocitic (glycoprotein IIb/IIIa) § Second line marker for AML
CD64 § Monocytic
CD68 § Monocytic
CD71 § Transferrin receptor § Erythroid marker
CD72 (DBA.44) § Hairy cell (+)
CD79a § Intracellular epitope of the alpha chain of the B-cell receptor § Highly sensitive and specific for B-lineage § Present from the earliest stages of B cell malignancy through to plasma cells (though a proportion of clonal plasma cells are negative)
CD 79b § Specific for B lineage § Reduced expression in CLL and hairy cell
CD117 § First line marker for AML § c-kit receptor (receptor for stem cell growth factor) § Postive in 2/3 cases of AML and less than 5% of ALL (most of which also expressed other myeloid markers eg CD13 or 33 and corresponded to early T Pro ALL
CD138 § Second line marker for acute B cell malignancies § Plasma cell marker
CD 235a (Glycophorin A) § Second line marker for AML § Erythroid marker (+ in M6 only)
CD246 (Alk) § Prognostic importance in anaplastic large cell lymphoma
BCL2 § Follicular lymphoma B cells – reactive in germinal centres § Poor prognosis in DLBCL
BCL6 § Nuclear transcription factor § Expressed by cytrocytes and centroblasts but not naïve B cells, mantle cells, memory B cells or plasmacells § Positive in Burkitt lymphoma, large-B cell lymphoma (good prognosis) and follicular lymphoma § Also undergoes mutations in somatic hypermutation as well as the IGV region
CytIg § Second line marker for acute B cell malignancies
Cyclin D1 § Mantle cell lymphoma (t11;14 translocation) or B-cell prolymphocytic leukaemia
EBV-LMP1 § EBV driven lymphomas
EMA (CD66a) § Plasma cells - +ve in anaplastic and large cell lymphoma
HLA DR § AML and ALL
Kappa / lambda § Difficult to do technically – best done by in situ hybridisation
Mast cell tryptase § Mast cells
MIB1 / (Ki67) § Proliferation marker § Can be helpful distinguishing MCL from CLL (50%+ in MCL v rarely + in CLL)
MUM1 § Plasma cells § Poor prognostic marker in DLBCL
MPO § Granulocytes
p21 § Upregulation associated with p53 overexpression
SmIg § Second line marker for acute B cell malignancies
TdT § First line non lineage restricted marker in acute leukaemia § Nuclear enzyme § T-ALL or T-lymphoblastic lymphoma § NB negative in DLBCL, T-PLL
TRAP § Hairy cell lymphoma
|
|
|